CompugenCGEN +3.75%60 9-Day RSI is 50.72 as of Jul. 02, 2026. GuruFocus rates CGEN with a GF Score™ of 60/100 and a GF Value™ of $5.21 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,422 Biotechnology companies, Compugen ranks worse than 66.95% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-02), Compugen's 9-Day RSI is 50.72.
The industry rank for Compugen's 9-Day RSI or its related term are showing as below:
CGEN's 9-Day RSI is ranked worse than 66.95% of 1422
companies
in the Biotechnology industry
Industry Median: 50.355
vs CGEN: 50.72
Compugen (NAS:CGEN) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Compugen 9-Day RSI Related Terms
CGEN vs VRTX, REGN, ALNY: 9-Day RSI Comparison
For the Biotechnology subindustry, Compugen's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Compugen 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Compugen's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Compugen's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Compugen (CGEN) has a 9-Day RSI of 50.72 as of Jul. 02, 2026. According to the industry distribution chart, Compugen ranks #952 out of 1422 companies in the Biotechnology industry, placing it in the top 66.9%.
Is Compugen's 9-Day RSI too high?
Compugen's current 9-Day RSI is 50.72. The Biotechnology industry median 9-Day RSI is 50.36. Compugen's value of 50.72 is 0.7% above this industry median. Based on the distribution chart, Compugen ranks #952 out of 1422 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Compugen has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Compugen's 9-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Compugen ranks #952 out of 1422 companies for 9-Day RSI. This places Compugen in the lower half of its industry. The industry median 9-Day RSI is 50.36. Compugen's value of 50.72 is 0.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 50.36, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Compugen's current 9-Day RSI of 50.72 is 0.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 50.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Compugen's current 9-Day RSI is 50.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compugen stock overvalued right now?
Based on GuruFocus' analysis, Compugen (CGEN) is currently considered Possible Value Trap. The stock's GF Value™ is $5.21, compared to a current price of $2.22 — trading 57.5% below its estimated fair value. The current 9-Day RSI is 50.72 and 0.7% above the Biotechnology industry median of 50.36. Compugen's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Compugen (CGEN), the current 9-Day RSI is 50.72 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Compugen (CGEN) Overvalued in 2026?
Based on GuruFocus' analysis, Compugen stock appears to be undervalued.
The current stock price of $2.22 is trading 57.5% below its estimated GF Value™ of $5.21.
GuruFocus considers Compugen to be Possible Value Trap.
Key valuation signals for CGEN:
9-Day RSI: 50.72
GF Value™: $5.21 vs. price of $2.22 (57.5% below fair value)
Industry Position: 0.7% above the Biotechnology median (#952 of 1422)
No single metric tells the full story. See the CGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.
60GF Score
Get the complete analysis for CGEN
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CGEN has been successfully added to your 